$NRSN News
Last published 1mo ago
- 1mo agoNRSNNeuroSense Provides Update on Nasdaq Listing CompliancePR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing...
- 1mo agoNRSNNeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities ConferencePR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...
- 1mo agoNRSNNeuroSense Provides Business Update and Progress for the First Half of 2026PR NewswireTherapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company focused on developing disease-modifying ...
- 2mo agoNRSNNeuroSense to Present at H.C. Wainwright 28th Annual Global Investment ConferencePR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...
- 2mo agoNRSNNeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALSPR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...
- 3mo agoNRSNNeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health CanadaPR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...
- 3mo agoNRSNNeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALSPR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...
- 4mo agoNRSNNeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"PR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...
- 4mo agoNRSNNeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALSPR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...
- 4mo agoNRSNNeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's DiseasePR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
- 4mo agoNRSNEverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the DotsPR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...
- 5mo agoNRSNNeuroSense Granted South Korean Patent Covering PrimeC Composition for ALSPR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments...
- 5mo agoNRSNNeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel CompositionPR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments...
- 6mo agoNRSNNeuroSense Announces Pricing of Insider-Led PIPE FinancingPR NewswireNeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
- 7mo agoNRSNNeuroSense Granted Brazilian Patent Covering PrimeC CompositionPR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments...
- 7mo agoNRSNNeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value RequirementsPR NewswireNeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company developing treatments for...
- 7mo agoNRSNNeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business UpdatePR NewswireNeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company developing treatments for...
- 7mo agoNRSNNeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's ReadoutPR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...
- 7mo agoNRSN/C O R R E C T I O N -- NeuroSense/PR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...
- 8mo agoNRSNJAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological ActivityPR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...
- 8mo agoNRSNPrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific ConferencePR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...
- 8mo agoNRSNNeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALSPR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...
- 9mo agoNRSNNeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC CompositionPR NewswireNeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
- 9mo agoNRSNNeuroSense Granted U.S. Patent for Treatment of Alzheimer's DiseasePR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
- 10mo agoNRSNWorld-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SABPR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
- 10mo agoNRSNNeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 StudyPR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
- 11mo agoNRSNNeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026PR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
- 11mo agoNRSNNeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALSPR NewswireNeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
- 1y agoNRSNNeuroSense to Host Investor Webinar on December 8, 2025PR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
- 1y agoNRSNNeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease BiomarkersPR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
- 1y agoNRSNNeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived NeuronsPR NewswireNeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
- 1y agoNRSNNeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market PricePR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
- 1y agoNRSNNeuroSense Provides Business Update and Progress for the First Half of 2025PR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe...
- 1y agoNRSNAward-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and CommunityPR NewswireNeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
- 1y agoNRSNNeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market LaunchPR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe...
- 1y agoNRSNNeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership UpdatePR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe...
- 1y agoNRSNNeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS TreatmentPR NewswireNeuroSense Therapeutics, Ltd. (NASDAQ: NRSN), a leading clinical-stage biotechnology company focused on developing treatments for severe...
- 1y agoNRSNNeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business UpdatesPR NewswireNeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a clinical-stage biotechnology company developing novel treatments for severe...
- 1y agoNRSNNeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology MeetingPR NewswireNeuroSense Therapeutics, Ltd. (NASDAQ: NRSN), a leading clinical-stage biotechnology company focused on developing treatments for severe...
- 1y agoNRSNNeuroSense Regains Compliance with Nasdaq's Minimum Equity RequirementPR NewswireNeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe...
- 1y agoNRSNNeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALSPR NewswireNeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
- 1y agoNRSNNeuroSense Provides Business Update and Third Quarter 2024 Financial ResultsPR NewswireNeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company developing novel treatments for severe...
- 1y agoNRSNNeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeCPR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
- 1y agoNRSNNeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALSPR NewswireNeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
- 1y agoNRSNNeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market PricePR NewswireNeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
- 1y agoNRSNNeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MNDPR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
- 2y agoNRSNNeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA SubmissionPR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
- 2y agoNRSNNew Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS PatientsPR NewswireNeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
- 2y agoNRSNNeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further UpdatesPR NewswireNeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...
- 2y agoNRSNNeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in CanadaPR NewswireNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ('NeuroSense'), a late-clinical stage biotechnology company developing novel treatments for severe...